Dihydrokainic acid

NMDA agonist, GLT-1 inhibitor.



LKT-D3328-M010	10 mg	323.00 USD

LKT-D3328-M025	25 mg	734.00 USD

The saturated analog of kainic acid. Reduction of the isopropylene side-chain destroys the affinity to binding sites. It enhances the antitumor activity of doxorubicin presumably acting as a glutamate transporter inhibitor .

PRODUCT PROPERTIES
Formula:		C₁₀H₁₇NO₄
MW:		215.25
CAS:		52497-36-6
Purity:		≥98%
Solubility:		Soluble in water (>110mg/mL).
Long Term Storage:		Ambient

Formula:

TECHNICAL DOCUMENTS Print as PDF	RELATED PRODUCTS No related products available
PRODUCT SUPPORT Technical Service Bulk Quantity Quote Customer Service	CATALOG SECTION Antitumor Reagents Other Products Glutamate Receptors (Ionotropic)/ R... Glutamate Receptors (Ionotropic)/ R... Glutamate Receptors (Ionotropic)/ R... Glutamate Receptors (Ionotropic)/ R...

Product Literature References

Effect of dihydrokainate on the antitumor activity of doxorubicin: Y. Sadzuka, et al.; Cancer Lett. 179, 157 (2002), Abstract;

Phylogenetic distribution of [3H]kainic acid receptor binding sites in neuronal tissue: E.D. London, et al.; Brain Res. 192, 463 (1980), Abstract;

Dihydrokainic acid

TECHNICAL DOCUMENTS

RELATED PRODUCTS

PRODUCT SUPPORT

CATALOG SECTION

Product Literature References